✨ Free AI Report
Celltrion, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Celltrion, Inc.
Company Research

Celltrion, Inc.: Business Overview, Financials & Competitive Analysis

Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. The company offers biosimilars including Remsima for rheumatoid arthritis and inflammatory bowel disease, Truxima for non-hodgkin's lymph...

Analyst-debate audio for Celltrion, Inc.

AskCyborg analysts argue the bull and bear cases for Celltrion, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
8/ 10Strong

Cyborg Score thesis

Celltrion is a high-growth South Korean biopharmaceutical leader positioned to capture significant value through biosimilar...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Biotechnology - Biosimilars & Innovative Therapeutics
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Celltrion, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Celltrion, Inc. Overview

Pro stress-test →

Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. The company offers biosimilars including Remsima for rheumatoid arthritis and inflammatory bowel disease, Truxima for non-hodgkin's lymphoma, Herzuma for metastatic breast and gastric cancer, and multiple other therapeutic products. Celltrion provides one-stop solutions for the entire process of biopharmaceutical business from R&D to clinical trials, regulatory affairs, production and distribution.

Strategic Profile

Pro stress-test →

Celltrion is transitioning from biosimilar excellence to next-generation innovative therapeutics with plans to expand manufacturing and R&D capabilities in the U.S. to support long-term growth and enhance supply resilience. Following a record year in 2025, Celltrion has entered a full-scale growth phase, targeting consolidated revenue of KRW 5.3 trillion in 2026.

Competitive Landscape

Pro stress-test →

Key competitors include Samsung Biologics, ALTEOGEN, Voronoi, and SK bioscience within South Korea's biosimilar sector. Celltrion competes globally with international biosimilar manufacturers while establishing differentiation through manufacturing scale and innovative pipeline development focused on ADCs and multi-specific antibodies.

Industry Context

Celltrion, Inc. operates in Biopharmaceutical/Biotechnology - Biosimilars & Innovative Therapeutics.

Key facts

Founded: 2002 · Headquarters: Incheon, South Korea · Employees: 2680 · Revenue: $2.6B (2024) · Market cap: $37.8B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Celltrion, Inc..

  • Five products transitioning into full-year sales cycles in 2026 with COGS ratio improving to 35.8% in Q4 2025, down from 63% in Q4 2023
  • Recent strategic moves include a 100.4 billion won CDMO deal with TEVA and acquisition of iQone Healthcare Switzerland for European expansion
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Unveiled strategic priorities for innovative drug pipelines including ADCs and msAbs at J.P. Morgan Healthcare Conference
  • August 2025Bid $504.3 million for Eli Lilly's BB50 Branchburg, NJ manufacturing site
  • +2 moreTrack every material event for Celltrion, Inc. as it happens. Explore monitoring →
Get alerted when Celltrion, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Samsung BiologicsBiopharmaceutical CDMO and biosimilar developer→SandozLeading global biosimilar manufacturer→Amgen BiosimilarsMajor biosimilar portfolio→Pfizer BiosimilarsLarge-scale biosimilar production→

Compare Celltrion, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Celltrion, Inc. operates in Biopharmaceutical/Biotechnology - Biosimilars & Innovative Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical/Biotechnology - Biosimilars & Innovative Therapeutics research →
NEW · MCP server

Ask your AI assistant about Celltrion, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Celltrion, Inc. and its top competitor on Cyborg Score”
“What did Celltrion, Inc. do this quarter?”
“Is Celltrion, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Celltrion, Inc. do?+
Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. The company offers biosimilars including Remsima for rheumatoid arthritis and inflammatory bowel disease, Truxima for non-hodgkin's lymph...
What is Celltrion, Inc.'s Cyborg Score?+
Celltrion, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Celltrion, Inc.'s main competitors?+
Named competitors include Samsung Biologics, Sandoz, Amgen Biosimilars, Pfizer Biosimilars. The full competitive landscape is in the AskCyborg report.
How can I get the full Celltrion, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Celltrion, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Celltrion, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.8UCB SATop companies in Biopharmaceutical by Cyborg Score